IL10 and neoplasm: The intratumoral administration of E7/nanoadjuvants regiments revealed that heterologous administration of nanovaccines elicited stronger immune responses compared with homologous regimens and naked nanoadjuvants, characterized by higher levels of IFN-γ, IL-10, and CD107, as a marker of CTL responses, as well as tumor growth inhibition.